Tag: caps
Zydus granted orphan drug designation by USFDA for ZYIL1 in treatment...
Orphan drug designation by USFDA for ZYIL1, provides eligibility for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemptions and seven-year marketing exclusivity
Disinfection caps market estimated to be valued at US$ 420 million...
Suppliers of disinfection caps are concentrating on product innovation and portfolio expansion to increase their ability to generate revenue from the global market
Zydus achieves positive Phase 2 Proof-of-Concept of NLRP3 inhibitor, ZYIL1 in...
The company is now planning to conduct further pivotal clinical trials and is committed to develop ZYIL1 for patients living with CAPS and other chronic inflammatory diseases
Zydus gets go ahead for phase-2 clinical trial of its novel...
The company will soon begin the Phase II (a) clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Cryopyrin-Associated Periodic Syndrome (CAPS), a rare life-long auto-inflammatory condition in Australia
Over 40% demand for biomedical textiles stimulated by non-implantable application: Study
Global biomedical textiles market to top US$ 6 Bn by 2031. Non-biodegradable, one of the segments, is projected to reach around US$ 4.5 Bn by 2031...........................